omo-103
Peptideexperimental
Clinical trial activity
4 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 28, 2021 (NCT04808362)
Timeline
Indications
Mechanism of action
- Myc proto-oncogene proteinINHIBITOR
MYC inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07089940 | Early Phase 1 (Phase 1) | Aug 1, 2025 | National Cancer Institute (NCI), OHSU Knight Cancer Institute |
| NCT06650514 | Phase 2 | Nov 30, 2024 | Harvard University, Memorial Sloan-Kettering Cancer Center, Oregon Health and Science University, Osteosarcoma Institute, Peptomyc S.L., Universidad Autonoma de Barcelona |
| NCT06059001 | Phase 1 | Aug 31, 2023 | Peptomyc S.L. |
| NCT04808362 | Phase 1/Phase 2 (Phase 2) | Apr 28, 2021 | Peptomyc S.L., Universidad Autonoma de Barcelona |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peptomyc S.L. | For profit | 3 | 2 | 2 | 2021 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 2 | 1 | 1 | 2021 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2024 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| OHSU Knight Cancer Institute | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Oregon Health and Science University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Osteosarcoma Institute | Academic/Hospital | 1 | 0 | 1 | 2024 |
8 organizations
Page 1 / 1